UNLOCK THE ONLY NONSTATIN ACTIVE IN BOTH THE LIVER AND INTESTINE TO REDUCE CIRCULATING LDL-C. ADD NEXLIZET.1

See how Bempedoic Acid Works

MOA video


NEXLIZET CONTAINS BEMPEDOIC ACID,* WHICH REDUCES CHOLESTEROL BIOSYNTHESIS IN THE LIVER1

The first and only ACL inhibitor, working complementary to statins to lower LDL-C1-4

Illustration of the mechanism of action of bempedoic acid in the liver

Bempedoic acid is not activated in skeletal muscle1-4

Illustration of how bempedoic acid is not activated in skeletal muscle


NEXLIZET also contains ezetimibe, which reduces cholesterol absorption in the intestine1-4

Ezetimibe decreases hepatic cholesterol stores, lowering circulating LDL-C1-4

Ezetimibe leads to: reduced cholesterol absorption, decreased hepatic cholesterol stores, and decreased LDL-C in the bloodstream

*Bempedoic acid is the active ingredient in NEXLETOL.5

MOA=mechanism of action; LDL-C=low-density lipoprotein cholesterol; ACL=adenosine triphosphate citrate lyase; ACSVL1=very long-chain acyl-coenzyme A synthetase-1; HMGR=3-hydroxy-3-methyl-glutaryl-coenzyme A reductase.

References: 1. NEXLIZET. Prescribing information. ESPERION Therapeutics, Inc.; 11/2020. 2. Pinkosky SL, Newton RS, Day EA, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;7(13457):1-13. 3. Pinkosky SL, Filippov S, Srivastava RA, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013;54(1):134-151. 4. Saeed A, Ballantyne CM. Bempedoic acid (ETC-1002): a current review. Cardiol Clin. 2018;36(2):257-264. 5. NEXLETOL. Prescribing information. ESPERION Therapeutics, Inc.; 2020.


DISCOVER NEXLIZET DOSING